Abstract
背景据报道,COPD中有真菌致敏的可变临床结果,目前尚不清楚哪种真菌以及哪种过敏原与最差的结局相关。重组而不是粗过敏原进行这种评估是未知的。
Methods前瞻性多中心评估稳定的警察D (n=614) was undertaken in five hospitals across three countries: Singapore, Malaysia, and Hong Kong. Clinical and serological assessment was performed against a panel of 35 fungal allergens including crude and recombinant曲霉和非 -曲霉过敏原。使用测量的敏化反应采用了无监督的聚类和拓扑数据分析(TDA)方法,以阐明是否存在敏化亚组及其相关的临床结果。
Results曲霉菌致敏性与COPD中的加重相关。无监督的聚类分析显示了两个“真菌敏化”组,一个以下为特征曲霉致敏和加重,肺功能较差和预后较差。该小组的分解性赋予了更差的结果。第二组,以cradosporiumsensitisation is more symptomatic. Significant numbers of individuals demonstrate sensitisation responses to only recombinant (as opposed to crude)曲霉菌allergens 1, 3, 5, and 6, and exhibit higher exacerbations, poorer lung function and an overall worse prognosis. TDA validated these findings and additionally identified a sub-group within “曲霉敏化的COPD富含频繁的加重器。
Conclusion曲霉sensitisation is a treatable trait in COPD. Measuring sensitisation responses to recombinant曲霉allergens identifies an important patient subgroup with poor COPD outcomes that remain overlooked by assessment of only crude曲霉过敏原。
Footnotes
This manuscript has recently been accepted for publication in theEuropean Respiratory Journal。它在我们的生产团队复制和排版之前以其公认的形式出版。在完成这些生产过程并批准了由此产生的证明之后,该文章将转移到最新一期ERJonline. Please open or download the PDF to view this article.
Conflict of interest: Pei Yee Tiew received honoraria for lectures and advisory board meetings paid to her hospital (Singapore General Hospital) from GlaxoSmithKline and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: Jayanth Kumar Narayana has nothing to disclose.
利益冲突:玛丽莲·斯威(Marilynn Swee Li Quek)无话可说。
利益冲突:Yan Ying Ang没有什么可披露的。
Conflict of interest: Fanny Wai San Ko has nothing to disclose.
Conflict of interest: Mau Ern Poh has nothing to disclose.
Conflict of interest: Tavleen Kaur Jaggi has nothing to disclose.
Conflict of interest: Huiying Xu has nothing to disclose.
Conflict of interest: Kai Xian Thng has nothing to disclose.
Conflict of interest: Mariko Siyue Koh received research grant support from Astra-Zeneca, honoraria for lectures and advisory board meetings paid to her hospital (Singapore General Hospital) and from GlaxoSmithKline, Astra-Zeneca, Novartis, Sanofi and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: Augustine Tee has nothing to disclose.
利益冲突:戴维·舒·舒恩(David Shu Cheong Hui)无话可说。
Conflict of interest: John Arputhan Abisheganaden has nothing to disclose.
利益冲突:Krasimira Tsaneva-Atanasova没有什么可披露的。
利益冲突:福蒂姆咀嚼报告的人al fees for consultancy from Sime Darby Technology Centre, First Resources Ltd, Genting Plantation and Olam International, outside the submitted work.
利益冲突:Sanjay H. Chotirmall在CSL Behring,Pneumagen Ltd和Boehringer Ingelheim的咨询委员会任职,在数据和安全监测委员会(DSMB)任职于Inovio Pharmaceuticals Inc.和Imam Abdulrahman Bin Faisal University,并接受来自Astra-Zeneca,全部在提交的工作之外。
- Received2022年3月9日。
- 公认July 24, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contactpermissions{at}ersnet.org